Gestational age determination and prevention of HIV perinatal transmission

Int J Gynaecol Obstet. 2006 Feb;92(2):176-80. doi: 10.1016/j.ijgo.2005.09.021. Epub 2005 Nov 23.

Abstract

Objective: To compare different methods of gestational age (GA) measurement for ensuring effective zidovudine (ZDV) prophylaxis to prevent mother-to-child transmission of HIV.

Methods: For 1398 HIV-infected women enrolled in a perinatal prevention trial, gestation durations were calculated based on GA estimated using ultrasound (US), date of last menstruation period (LMP), first fundal height (FH(1)), and a specific algorithm was developed to provide a "reference" GA. The performance of each GA estimate was evaluated by the percentage of women who would have received > or =8 weeks ZDV, if prophylaxis was initiated at 28 weeks.

Results: The performances of the algorithm, US, LMP, and FH(1) were 95.5%, 94.8%, 88.4%, and 83.7%, respectively. US and FH(1) were significantly better when estimated before and after 24 weeks, respectively.

Conclusion: In situations where no US is available and LMP is not or imprecisely known, FH(1) can be used after 24 weeks to schedule ZDV initiation date.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Female
  • Gestational Age*
  • HIV Infections / prevention & control*
  • HIV Infections / transmission*
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Pregnancy
  • Pregnancy Outcome
  • Thailand
  • Time Factors
  • Zidovudine / administration & dosage
  • Zidovudine / therapeutic use*

Substances

  • Anti-HIV Agents
  • Zidovudine